MIT Researchers See Alternative To Common Colorectal Cancer Drug
A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found. Both compounds are analogues of cisplatin, a potent anticancer agent, but the newly investigated compound, known as cDPCP, may better target colorectal cells, potentially sparing other body tissues from damage.
Naviscan's PEM Flex trade; Detects Smallest Cancers Better Compared To MRI In An Independent Study
Naviscan PET Systems, a company specializing in organ specific high resolution PET scanners, announced today at the Society of Nuclear Medicine - new clinical data using the PEM Flex scanner in breast cancer management. The PEM Flex™ Solo II is a commercially available, FDA cleared scanner that utilizes PET technology for the breast application known as positron emission mammography, PEM.
Champions Biotechnology Begins Preclinical Development Of Its Lead Oncology Drug Candidate
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announced that it has begun preclinical development of the lead Benzoylphenylurea (BPU) sulfur analog compound that the Company acquired last year.
Melanoma Risk - People Obey Screening Recommendations Better After Genetic Testing - Whether Or Not They Test Positive, Study
When people know the results of genetic tests confirming they have inherited an increased risk of developing melanoma, they follow skin cancer screening recommendations more proactively - much like those who have already been diagnosed with the potentially deadly disease, according to results of a study completed at the University of Utah's Huntsman Cancer Institute and published in the June issue of Cancer Epidemiology, Biomarkers & Prevention.
New Therapy Shows Promise For Fighting Treatment-Resistant Cancer Cells
A gene radiotherapy system that detects and treats cancer cells that are resistant to traditional forms of chemotherapy and radiation showed success in the laboratory and could eventually prove beneficial for cancer patients, according to researchers at SNM's 55th Annual Meeting.
PET CT Scan Could Be Valuable Noninvasive Tool For Determining Stages Of Ovarian Cancer
Combined positron emission tomography (PET) and computed tomography (CT) scanning of patients in the early stages of ovarian cancer can enable physicians to determine whether the cancer has spread to nearby lymph nodes without having to perform surgery, according to researchers at the SNM's 55th Annual Meeting.
Potential Of Targeted Therapies For Cancer
A new study, presented at the SNM 55th Annual Meeting, shows the potential to pre-target the treatment of cancer cells - bringing personalized medicine one step closer from the laboratory to patients. By combining new molecular imaging techniques with targeted therapy, pretargeting offers cancer patients a more individualized treatment that can increase the effectiveness of therapies and minimize discomfort experienced during treatment.
Comment From Breakthrough Breast Cancer Re Alan Johnson Announcement This Afternoon That There Will Be A Review Into Co-Payment For NHS Services, UK
Jeremy Hughes, Chief Executive of Breakthrough Breast Cancer says: "Today's announcement to review the policy on co-payments in the NHS is welcome news and should provide much needed clarity on this complex issue. "Breakthrough Breast Cancer believes that access to treatments should be based on clinical need and not cost.
Feds Crack Down On Fake Cancer Cures
The US Food and Drug Administration (FDA) is cracking down on individuals and companies that market treatment products while fraudulently claiming them to be effective at preventing, treating or curing cancer. The FDA, a federal agency in the US government's executive Department of Health and Human Services, announced yesterday, 17th June, that it had sent "warning letters" to 23 US firms and two foreign individuals.
Cervical Cancer Screenings Lacking In Developing Countries
A study published in the open-access journal PLoS Medicinehas found that women in the developing world are not getting thecervical cancer screenings that they need. Researcher Emmanuela Gakidou(University of Washington, Seattle, USA) and colleagues report thatalthough women in the developing world have the highest risk ofdeveloping cervical cancer, few are effectively screened.